DermTech and DermatologistOnCall Enter Agreement to Improve Access to the DermTech Melanoma Test with Noninvasive, At-Home Sample Collection

LA JOLLA, Calif. & PITTSBURGH–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, and DermatologistOnCall, a leading dermatology telehealth provider in the U.S., announced today an agreement to make the DermTech Melanoma Test available through DermatologistOnCall’s telemedicine platform. The millions of patients served through DermatologistOnCall will now have increased access to DermT
Click here to view original post